You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Radionuclide Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy

Recruiting
  • PSMA-positive Metastatic Castration-resistant Prostate Cancer Treated With PSMA Radionuclide Therapy
  • PSMA radionuclide therapy
  • Dallas, Texas
    Methodist Dallas Medical Center
Aug 9, 2023

Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy Trial in Rotterdam (olaparib)

Recruiting
  • Neuroendocrine Tumors
  • Peptide Receptor Radionuclide Therapy
  • Rotterdam, South Holland, Netherlands
    Erasmus MC
May 19, 2023

Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma Trial (177Lu-DOTATOC)

Not yet recruiting
  • Neuroendocrine Tumors
  • +2 more
  • (no location specified)
Sep 13, 2023

Advanced Malignant Tumor Trial in Beijing ([ Lu-177]-Catalase)

Recruiting
  • Advanced Malignant Neoplasm
  • [ Lu-177]-Catalase
  • Beijing, Beijing, China
    Zhi Yang
Aug 2, 2023

AminoMedixTM for Kidney Protection During Radionuclide Therapy

Completed
  • Radiation Nephropathy
    • (no location specified)
    Mar 22, 2023

    Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma Trial (Lu-177 DOTATATE

    Not yet recruiting
    • Bronchial and Thymic Neuroendocrine Tumour
    • +3 more
    • Lu-177 DOTATATE (Lutathera®)
    • (no location specified)
    Nov 1, 2023

    Metastatic Clear Cell Renal Cell Carcinoma, With Positive PSMA Expression at Tumor Sites Trial (177Lu-PSMA-1

    Not yet recruiting
    • Metastatic Clear Cell Renal Cell Carcinoma
    • With Positive PSMA Expression at Tumor Sites
    • 177Lu-PSMA-1 (radiopharmaceutical)
    • (no location specified)
    Sep 26, 2023

    Neuroendocrine Tumors Trial (Lutathera)

    Not yet recruiting
    • Neuroendocrine Tumors
    • (no location specified)
    Aug 23, 2022

    Metastatic Malignant Tumor in the Liver, Neuroendocrine Tumor Trial in San Francisco (procedure, biological, device)

    Recruiting
    • Metastatic Malignant Neoplasm in the Liver
    • Neuroendocrine Neoplasm
    • Arterial Embolization
    • +3 more
    • San Francisco, California
      University of California, San Francisco
    Dec 22, 2022

    Solid Tumor, Unspecified, Adult Trial in Singapore (177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004

    Not yet recruiting
    • Solid Tumor, Unspecified, Adult
    • 177Lu-LNC1004 Injection group 1 radionuclide therapy
    • +3 more
    • Singapore, Singapore
      National University Cancer Institute, Singapore National Univers
    Feb 1, 2023

    Prostate Cancer Metastatic Trial in New York (Actinium-J591, Stereotactic Body Radiation Therapy, Androgen Deprivation Therapy)

    Not yet recruiting
    • Prostate Cancer Metastatic
    • New York, New York
      Weill Cornell Medicine - New York Presbyterian Hospital
    Oct 3, 2022

    Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

    Not yet recruiting
    • Digestive System Neuroendocrine Tumor G1
    • +5 more
    • Tumor Debulking
    • +5 more
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Aug 23, 2023

    HRQoL During PRRT in Patients With NETs

    Completed
    • Neuroendocrine Tumors
    • +2 more
      • (no location specified)
      Jun 16, 2022

      Pancreatic Neuroendocrine Tumor, Pancreas Cancer Trial in Chicago (cytoreductive surgery, Lutathera - a small molecule used in

      Not yet recruiting
      • Pancreatic Neuroendocrine Tumor
      • Pancreas Cancer
      • cytoreductive surgery
      • +2 more
      • Chicago, Illinois
        The University of Chicago
      Nov 8, 2022

      Merkel Cell Carcinoma Trial (Pembrolizumab, Lutetium Lu 177 dotatate)

      Not yet recruiting
      • Merkel Cell Carcinoma
      • (no location specified)
      Oct 12, 2022

      Pancreatic Neuroendocrine Tumor Trial in Milano (peptide receptor radionuclide therapy with Y-90-DOTATOC)

      Recruiting
      • Pancreatic Neuroendocrine Tumor
      • peptide receptor radionuclide therapy with Y-90-DOTATOC
      • Milano, Italy
      • +1 more
      Sep 30, 2022

      Prostatic Tumors, Castration-Resistant Trial in Rotterdam (Radionuclide Therapy)

      Recruiting
      • Prostatic Neoplasms, Castration-Resistant
      • Radionuclide Therapy
      • Rotterdam, Zuid-Holland, Netherlands
        Erasmus Medical Center
      Jun 5, 2023

      Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma

      Recruiting
      • Refractory Thyroid Gland Carcinoma
      • +3 more
      • 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
      • +2 more
      • Xiamen, China
        The First Affiliated Hospital of Xiamen University
      Nov 3, 2022

      Neuroblastoma Trial in Lille, Lyon, Toulouse (PRRT with 177Lu-DOTATATE)

      Not yet recruiting
      • Neuroblastoma
      • PRRT with 177Lu-DOTATATE
      • Lille, France
      • +2 more
      Nov 8, 2022

      Hepatocellular Carcinoma Trial in Birmingham ([68Ga]DOTATATE-PET/MRI)

      Completed
      Has Results
      • Hepatocellular Carcinoma
      • Birmingham, Alabama
        University of Alabama at Birmingham Medical Center
      Dec 16, 2022

      (PRRT) for the Treatment of Neuroendocrine Tumors

      Enrolling by invitation
      • Neuroendocrine Tumors
      • Peptide Receptor Radionuclide Therapy
      • Dallas, Texas
        Methodist Dallas Medical Center
      Oct 27, 2021

      Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea Trial in Iowa City (Telotristat ethyl, Peptide Receptor Radionuclide

      Withdrawn
      • Neuroendocrine Tumors
      • +2 more
      • Telotristat ethyl
      • +2 more
      • Iowa City, Iowa
        University of Iowa Hospital and Clinics
      Feb 9, 2022

      Nasopharyngeal Carcinoma Trial in Xiamen (177Lu-EB-LM3 1, 177Lu-EB-LM3 2)

      Recruiting
      • SSTR2-positive Tumors
      • 177Lu-LNC1010 1
      • +2 more
      • Xiamen, China
        The First Affiliated Hospital of Xiamen University
      Nov 20, 2022

      Melanoma Trial in Clermont-Ferrand ([131I]ICF01012 (therapeutic dose level 1), [131I]ICF01012 (therapeutic dose level 2),

      Recruiting
      • Melanoma
      • [131I]ICF01012 (therapeutic dose level 1)
      • +3 more
      • Clermont-Ferrand, France
      • +1 more
      Jan 27, 2022

      Neuroendocrine Tumors, Hyperthyroidism, Thyroid Cancer Trial in London (Nuclear Medicine whole-body, SPECT/CT imaging., PET/CT

      Recruiting
      • Neuroendocrine Tumors
      • +3 more
      • Nuclear Medicine whole-body
      • +4 more
      • London, United Kingdom
        Guy's and St Thomas Hospitals Foundation Trust
      Jan 5, 2022